Search results for "endpoints"

showing 6 items of 6 documents

The more the merrier? Scoring, statistics and animal welfare in experimental autoimmune encephalomyelitis.

2016

Experimental autoimmune encephalomyelitis (EAE) is a frequently used animal model for the investigation of autoimmune processes in the central nervous system. As such, EAE is useful for modelling certain aspects of multiple sclerosis, a human autoimmune disease that leads to demyelination and axonal destruction. It is an important tool for investigating pathobiology, identifying drug targets and testing drug candidates. Even though EAE is routinely used in many laboratories and is often part of the routine assessment of knockouts and transgenes, scoring of the disease course has not become standardized in the community, with at least 83 published scoring variants. Varying scales with diffe…

0301 basic medicineEncephalomyelitis Autoimmune Experimental3400 General Veterinary610 Medicine & healthAnimal WelfareDisease course03 medical and health sciences0302 clinical medicineAnimal modelAnimals LaboratorymedicineAnimalsStatistical analysis10239 Institute of Laboratory Animal SciencerefinementAutoimmune diseasescoring scalesGeneral VeterinaryAnimal Welfare (journal)business.industryEAEMultiple sclerosisExperimental autoimmune encephalomyelitismedicine.diseasehumane endpointsDisease Models Animal030104 developmental biologyResearch DesignAnimals Domestic570 Life sciences; biologyAnimal Science and Zoology1103 Animal Science and ZoologybusinessNeuroscience030217 neurology & neurosurgeryLaboratory animals
researchProduct

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

2020

Background: Radiology-based outcomes, such as progression-free survival (PFS) and objective response rate (ORR), are used as surrogate endpoints in oncology trials. We aimed to assess the surrogacy relationship of PFS with overall survival (OS) in clinical trials of systemic therapies targeting advanced hepatocellular carcinoma (HCC) by novel meta-regression methods. Methods: A search of databases (PubMed, American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO) Meeting Libraries, Clinicaltrials.gov) for trials of systemic therapies for advanced HCC reporting both OS and PFS was performed. Individual patient data were extracted from PFS and OS Kaplan&nd…

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentoverall survivallcsh:RC254-282ArticleSettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpointmedicineOverall survival030212 general & internal medicineProgression-free survivalneoplasmsSettore MED/12 - Gastroenterologiabusiness.industrySurrogate endpointImmunotherapyhepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensConfidence intervalClinical trialOncologyQuartile030220 oncology & carcinogenesisHepatocellular carcinomasurrogate endpointsimmunotherapySettore SECS-S/01 - Statisticabusinessprogression-free survivalCancers
researchProduct

Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?

2021

Background& Aims: Time to progression (TTP) and progression-free survival (PFS) are commonly used as surrogate endpoints in oncology trials. We aimed to assess the surrogacy relationship of TTP and PFS with overall survival (OS) in studies of transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (u-HCC) by innovative methods. Methods: A search of databases for studies of TACE for u-HCC reporting both OS and TTP or PFS was performed. Individual patient data were extracted from TTP/PFS and OS Kaplan-Meier curves of TACE arms. Pooled median TTP and OS were obtained from random-effect model. The surrogate relationships of hazard ratios (HRs) and median TTP for OS …

Oncologymedicine.medical_specialtyCarcinoma Hepatocellularoverall survivaltransarterial chemoembolizationtime to progressionSystemic therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalsurrogate endpointHumansProgression-free survivalChemoembolization TherapeuticneoplasmsNeoplasm StagingHepatologybusiness.industrySurrogate endpointLiver NeoplasmsHazard ratiohepatocellular carcinomamedicine.diseaseCombined Modality TherapyConfidence intervalTreatment Outcomesurrogate endpoints030220 oncology & carcinogenesisHepatocellular carcinomaRadiological weaponDisease Progression030211 gastroenterology & hepatologyRadiologybusinessprogression-free survival
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches

2018

Abstract Background Primary headache are prevalent and debilitating disorders. Acute pain cessation is one of the key points in their treatment. Many drugs have been studied but the design of the trials is not usually homogeneous. Efficacy of the trial is determined depending on the selected primary endpoint and usually other different outcomes are measured. We aim to critically appraise which were the employed outcomes through a systematic review. Methods We conducted a systematic review of literature focusing on studies on primary headache evaluating acute relief of pain, following the PRISMA guideline. The study population included patients participating in a controlled study about sympt…

medicine.medical_specialtyNeurologyHeadache Disorders Primaryendpointspractice guidelines as topiclcsh:MedicineTriptansPlacebopatient complianceanti-inflammatory agentsnon-steroidal03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineprimarymedicineClinical endpoint030212 general & internal medicinehumansdisabled personsclinical trialsnon-steroidal anti-inflammatorybusiness.industryAnti-Inflammatory Agents Non-Steroidallcsh:RtryptaminesCorrectionacuteGeneral MedicineGuidelineacute; clinical trials; endpoints; non-steroidal anti-inflammatory; primary headaches; prisma-guidelines; triptans; anti-inflammatory agents non-steroidal; chronic disease; disabled persons; headache disorders primary; humans; patient compliance; practice guidelines as topic; treatment outcome; tryptamines; quality of lifemedicine.diseasetriptansClinical trialAnesthesiology and Pain Medicineheadache disordersMigrainequality of lifetreatment outcomeprimary headachesNeurology (clinical)prisma-guidelinesbusinesschronic disease030217 neurology & neurosurgeryResearch Articlemedicine.drug
researchProduct

Toxicity of retene and pyrene on fish at different light conditions

2011

whitefishhaukinorthern pikelohimyrkyllisyysprotein endpointsympäristön tilaphototoxicityeleytheroembryoskirjolohipyreenitympäristömyrkytkalatfishluonnonvalotoxityrainbow troutenvironmental chemicalshiilivedytqPCRjuvenileympäristövaikutuksetsiikamikrobiologiareteenittranscriptomemicroarrayvaloaromaattiset hiilivedyt
researchProduct